IDEAYA

Protocol Number: IDE196-009

Principal Investigator: Thomas Aaberg, Jr., MD

Phase 2 multi-center open-label IDE196 study in patients with primary uveal melanoma requiring either enucleation or plaque brachytherapy. Patients will be treated in a neoadjuvant setting for up to 6 months (or maximum benefit) followed by primary local therapy. An additional 6 months of adjuvant treatment to follow with long-term follow-up (up to 3 years) to assess visual outcome, disease recurrence, and development of metastatic disease.

Please click here for more detailed clinical information on the study.